Westmore · UDRP DecisionMerckcovidpill.com
The Panel ordered transfer of <merckcovidpill.com>. It found the domain confusingly similar to Complainant’s MERCK trademark, that Respondent had no rights or legitimate interests, and that registration one day after widespread news of Complainant’s Covid-19 pill, followed by use of the domain to resolve to an unrelated website advertising books for sale, established bad-faith registration and use.
The timeline behind merckcovidpill.com
Registration, the decision and the archived record of what this domain actually displayed — from public RDAP and the Internet Archive.
Westmore reconstructs the full history behind merckcovidpill.com — from public RDAP and the Internet Archive — as part of UDRP Intelligence:
The case illustrates opportunistic bad faith where a domain incorporating a longstanding pharmaceutical mark and a newly announced product description was registered immediately after major news coverage. The close timing, semantic match to the announcement, and unrelated commercial destination collectively made targeting particularly clear.
Result of record. The panel's reasoning and decisive facts behind each element are in the Intelligence dossier below.
WIPO Arbitration and Mediation Center ADMINISTRATIVE PANEL DECISION Merck Sharp & Dohme Corp. v. Whois Agent, Domain Protection Services, Inc. / John Montgomery, Right Track Productions Case No. D2021-3623 1. The Parties Complainant is Merck Sharp & Dohme Corp., United States of America (“United States”) (hereinafter, “Complainant”), represented by Covington & Burling LLP, United States. Respondent is Whois Agent, Domain Protection Services, Inc., United States/ John Montgomery, Right Track Productions, United States (hereinafter, “Respondent”). 2. The Domain Name and Registrar The disputed domain name <merckcovidpill.com> is registered with Name.com, Inc. (the “Registrar”). 3. Procedural History The Complaint was filed with the WIPO Arbitration and Mediation Center (the “Center”) on October 29, 2021. On November 1, 2021, the Center transmitted by email to the Registrar a request for registrar verification in connection with the disputed domain name. On November 2, 2021, the Registrar transmitted by email to the Center its verification response disclosing registrant and contact information for the disputed domain name, which differed from the named Respondent and contact information in the Complaint. The Center sent an email communication to Complainant on November 5, 2021, providing the registrant and contact information disclosed by the Registrar, and inviting Complainant to submit an amendment to the Complaint. Complainant filed an amended Complaint on November 9, 2021. The Center verified that the Complaint together with the amended Complaint (hereinafter, the “Complaint”) satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy” or “UDRP”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”). In accordance with the Rules, paragraphs 2 and 4, the Center formally notified Respondent of the Complaint, and the proceedings commenced on November 10, 2021. In accordance with the Rules, paragraph 5, the due date for Response was November 30, 2021. Respondent did not submit any Response. Accordingly, the Center notified Respondent’s default on December 6, 2021. The Center appointed M. Scott Donahey as the sole panelist in this matter on December 22, 2021. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7. 4. Factual Background Complainant is a research-intensive biopharmaceutical company, developing medicines, including cancer drugs, vaccines, antivirals anti-infectives and therapeutics with applications worldwide. Complainant is the owner of United States Patent and Trademark Office issued Trademark registrations in the MERCK trademarks, the earliest of which dates back to February 15, 1916. These trademarks have long been used in commerce to identify Complainant, its drug products, and related pharmaceutical products and services. Since February 1887, Complainant has continuously promoted its business and products under the MERCK name and mark. Complaint, Annex D. On October 1, 2021, Merck publicly announced clinical trial results for an investigational viral pill for use in the treatment of Covid. Complaint, Annex E. The viral pill will be marketed in the United States under the MERCK trademark. Complainant’s new Covid-19 pill received significant news coverage in major news publications. Complaint, Annex F. In mid to late October Complainant learned that Respondent had registered the disputed domain name. Complaint, Annex B. The disputed domain name resolved to a website at “www.paulcraigroberts.org”, a website posting conspiracy theories and anti-medicine information. Complaint, Annex G. The website advertises books written by Paul Craig Robers and contains links to purchase such books and to donate to an organization called the Institute for Political Economy. Id. Respondent registered the disputed domain name on October 2, 2021. 5. Parties’ Contentions A. Complainant Complainant asserts that the disputed domain name is confusingly similar to its registered trademarks. Complainant contends that Respondent has no rights or legitimate interests in respect of the disputed domain name. Complainant asserts that Respondent registered and is using the disputed domain name in bad faith. B. Respondent Respondent did not reply to Complainant’s contentions. 6. Discussion and Findings “A Panel shall decide a complaint on the basis of the statements and documents submitted and in accordance with the Policy, these Rules and any rules and principles of law that it deems applicable.” Paragraph 15(a) of the Rules. Paragraph 4(a) of the Policy directs that the complainant must prove each of the following: (i) that the domain name registered by the respondent is identical or confusingly similar to a trademark or service mark in which the complainant has rights; and, (ii) that the respondent has no rights or legitimate interests in respect of the domain name; and, (iii) that the domain name has been registered and is being used in bad faith. A. Identical or Confusingly Similar The disputed domain name consists of Complainant’s well known MERCK trademark and the words “covid” and “pill.” “Covid” is an infectious disease caused by the SARS-CoV-2 virus. Pill is a tablet containing compounds which fight disease. The MERCK trademark is clearly recognizable in the disputed domain name. Accordingly, the Panel finds that the disputed domain name is confusingly similar to Complainant’s trademark. B. Rights or Legitimate Interests While the overall burden of proof in UDRP proceedings is on the complainant, UDRP panels have recognized that proving a respondent lacks rights or legitimate interests in a domain name may result in the almost impossible task of “proving a negative”, requiring information that is often primarily within the knowledge or control of the respondent. As such, where a complainant makes out a prima facie case that the respondent lacks rights or legitimate interests, the burden of production on this element shifts to the respondent to come forward with relevant evidence demonstrating rights or legitimate interests in the domain name. If the respondent fails to come forward with such relevant evidence, the complainant is deemed to have satisfied the second element. WIPO Overview of WIPO Panel Views on Selected UDRP Questions, Third Edition, section 2.1. In the present case, Complainant alleges that Respondent has no rights or legitimate interests in respect of the disputed domain name and Respondent has failed to assert any such rights. Accordingly, the Panel finds that Respondent has no rights or legitimate interests in respect of the disputed domain name. C. Registered and Used in Bad Faith Respondent registered the disputed domain name one day after the news was published around the world that Complainant had discovered and was marketing a pill which combatted Covid-19, a disease caused by the SARS-CoV-2 virus. Respondent used the disputed domain name to resolve to a website, which promoted a controversial political theory wholly unrelated to the disease the pill was intended to fight. At the website to which the disputed domain name resolves, the book written by the proponent of the political theory was advertised for sale. Accordingly, the Panel finds that the disputed domain name was registered and is being used in bad faith. 7. Decision For the foregoing reasons, in accordance with paragraphs 4(i) of the Policy and 15 of the Rules, the Panel orders that the disputed domain name, <merckcovidpill.com>, be transferred to Complainant. M. Scott Donahey Sole Panelist Date: December 30, 2021
Source of record: WIPO . Reproduced for research; WIPO is the authoritative source.
What Westmore sees around merckcovidpill.com
The decision is only the record. Westmore connects it to the cases, authorities, panelists, parties and domain evidence surrounding it.
A short, grounded explanation drawn only from this decision's record — not legal advice or a prediction.
Grounded in the Westmore record for this decision. Research/informational only — not legal advice or a prediction of any outcome.
The decision is only the beginning.
You've seen what happened. Now discover the deeper intelligence behind the case, the panelist, the parties and the authorities that matter.
Go beyond the public record: see how this case has been cited, find comparable decisions, analyze the panelist and apply the relevant authorities to your Matter.
Westmore Professional · $395/month
Research with UDRP IntelligenceWestmore AI drafts an attorney-review-ready UDRP response from your facts, grounded in the exact panel and closest precedent.
$895 one-time per matter · no subscription required. Self-help drafting aid — not legal advice.
Build your responseWestmore UDRP records draw on WIPO-indexed decisions and are provided for research and informational purposes only. Not legal advice, a clearance opinion, or a prediction of any outcome.